Terumo Corporation Logo

Terumo Corporation

4543.T

(3.0)
Stock Price

3.036,00 JPY

9.4% ROA

9.02% ROE

37.07x PER

Market Cap.

4.363.255.056.690,00 JPY

13.73% DER

0.82% Yield

12.2% NPM

Terumo Corporation Stock Analysis

Terumo Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Terumo Corporation Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (21%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

3 Dividend Growth

Investors can be encouraged by the company's strong dividend growth over the past five years, highlighting its ability to generate consistent returns and provide an attractive investment opportunity.

4 ROE

ROE in an average range (8%) suggests satisfactory profitability and decent utilization of shareholders' equity.

5 ROA

The stock's ROA (8.77%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

6 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

7 Net Profit Growth

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

8 Dividend

Investors can take comfort in the fact that the company has consistently distributed dividends over the past three years, demonstrating a commitment to rewarding shareholders.

9 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (43.845) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

10 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.2x) suggests it's overvalued, potentially making it an expensive investment.

11 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

Terumo Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Terumo Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Terumo Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Terumo Corporation Revenue
Year Revenue Growth
2000 176.049.000.000
2001 187.082.100.000.000 99.91%
2002 200.625.000.000 -93149.64%
2003 215.195.000.000 6.77%
2004 230.003.000.000 6.44%
2005 247.048.000.000 6.9%
2006 276.439.000.000 10.63%
2007 306.381.000.000 9.77%
2008 302.746.000.000 -1.2%
2009 316.009.000.000 4.2%
2010 328.214.000.000 3.72%
2011 386.686.000.000 15.12%
2012 402.294.000.000 3.88%
2013 467.359.000.000 13.92%
2014 489.506.000.000 4.52%
2015 525.026.000.000 6.77%
2016 514.164.000.000 -2.11%
2017 587.775.000.000 12.52%
2018 599.481.000.000 1.95%
2019 628.897.000.000 4.68%
2020 613.842.000.000 -2.45%
2021 703.303.000.000 12.72%
2022 820.209.000.000 14.25%
2023 914.484.000.000 10.31%
2023 921.863.000.000 0.8%
2024 1.032.776.000.000 10.74%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Terumo Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 27.129.000.000 100%
2013 30.130.000.000 9.96%
2014 29.360.000.000 -2.62%
2015 33.147.000.000 11.42%
2016 32.378.000.000 -2.38%
2017 41.342.000.000 21.68%
2018 47.700.000.000 13.33%
2019 50.600.000.000 5.73%
2020 49.100.000.000 -3.05%
2021 51.800.000.000 5.21%
2022 61.600.000.000 15.91%
2023 0 0%
2023 69.060.000.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Terumo Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 58.227.000.000
2001 62.227.000.000 6.43%
2002 67.346.000.000 7.6%
2003 73.639.000.000 8.55%
2004 76.657.000.000 3.94%
2005 87.419.000.000 12.31%
2006 94.871.000.000 7.85%
2007 101.259.000.000 6.31%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 84.413.000.000 100%
2013 33.000.000 -255696.97%
2014 0 0%
2015 0 0%
2016 0 0%
2017 212.363.000.000 100%
2018 226.334.000.000 6.17%
2019 235.144.000.000 3.75%
2020 228.566.000.000 -2.88%
2021 250.891.000.000 8.9%
2022 299.861.000.000 16.33%
2023 331.044.000.000 9.42%
2023 344.979.000.000 4.04%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Terumo Corporation EBITDA
Year EBITDA Growth
2000 42.342.000.000
2001 39.672.000.000 -6.73%
2002 41.321.000.000 3.99%
2003 48.860.000.000 15.43%
2004 58.550.000.000 16.55%
2005 60.665.000.000 3.49%
2006 74.482.000.000 18.55%
2007 86.663.000.000 14.06%
2008 73.193.000.000 -18.4%
2009 83.688.000.000 12.54%
2010 77.348.000.000 -8.2%
2011 88.735.000.000 12.83%
2012 85.520.000.000 -3.76%
2013 104.876.000.000 18.46%
2014 112.941.000.000 7.14%
2015 119.241.000.000 5.28%
2016 116.002.000.000 -2.79%
2017 151.457.000.000 23.41%
2018 152.620.000.000 0.76%
2019 164.195.000.000 7.05%
2020 153.329.000.000 -7.09%
2021 176.344.000.000 13.05%
2022 190.391.000.000 7.38%
2023 226.012.000.000 15.76%
2023 267.658.000.000 15.56%
2024 265.664.000.000 -0.75%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Terumo Corporation Gross Profit
Year Gross Profit Growth
2000 87.028.000.000
2001 186.985.284.000.000 99.95%
2002 98.645.000.000 -189453.74%
2003 110.292.000.000 10.56%
2004 123.765.000.000 10.89%
2005 135.671.000.000 8.78%
2006 153.327.000.000 11.52%
2007 168.202.000.000 8.84%
2008 158.240.000.000 -6.3%
2009 166.350.000.000 4.88%
2010 170.798.000.000 2.6%
2011 204.640.000.000 16.54%
2012 205.689.000.000 0.51%
2013 242.011.000.000 15.01%
2014 256.026.000.000 5.47%
2015 284.901.000.000 10.14%
2016 278.000.000.000 -2.48%
2017 319.333.000.000 12.94%
2018 326.497.000.000 2.19%
2019 343.933.000.000 5.07%
2020 326.623.000.000 -5.3%
2021 369.341.000.000 11.57%
2022 417.370.000.000 11.51%
2023 473.824.000.000 11.91%
2023 555.920.000.000 14.77%
2024 550.280.000.000 -1.02%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Terumo Corporation Net Profit
Year Net Profit Growth
2000 16.639.000.000
2001 14.441.000.000 -15.22%
2002 18.155.000.000 20.46%
2003 19.792.000.000 8.27%
2004 27.134.000.000 27.06%
2005 32.457.000.000 16.4%
2006 37.232.000.000 12.82%
2007 43.382.000.000 14.18%
2008 36.878.000.000 -17.64%
2009 40.721.000.000 9.44%
2010 32.338.000.000 -25.92%
2011 24.167.000.000 -33.81%
2012 47.014.000.000 48.6%
2013 34.096.000.000 -37.89%
2014 38.470.000.000 11.37%
2015 50.676.000.000 24.09%
2016 54.225.000.000 6.54%
2017 91.295.000.000 40.6%
2018 79.470.000.000 -14.88%
2019 85.211.000.000 6.74%
2020 77.268.000.000 -10.28%
2021 88.813.000.000 13%
2022 89.325.000.000 0.57%
2023 110.168.000.000 18.92%
2023 106.374.000.000 -3.57%
2024 135.564.000.000 21.53%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Terumo Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 20
2001 18 -17.65%
2002 23 22.73%
2003 25 8.33%
2004 34 29.41%
2005 40 12.82%
2006 47 15.22%
2007 55 16.36%
2008 48 -17.02%
2009 54 11.32%
2010 43 -26.19%
2011 32 -35.48%
2012 62 49.18%
2013 45 -38.64%
2014 51 12%
2015 68 25.37%
2016 76 11.84%
2017 121 37.19%
2018 54 -128.3%
2019 57 5.36%
2020 51 -9.8%
2021 59 12.07%
2022 60 1.69%
2023 148 59.86%
2023 72 -107.04%
2024 91 21.98%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Terumo Corporation Free Cashflow
Year Free Cashflow Growth
2000 9.896.000.000
2001 14.964.000.000 33.87%
2002 23.356.000.000 35.93%
2003 40.441.000.000 42.25%
2004 40.948.000.000 1.24%
2005 41.184.000.000 0.57%
2006 25.122.000.000 -63.94%
2007 53.729.000.000 53.24%
2008 11.374.000.000 -372.38%
2009 47.636.000.000 76.12%
2010 24.595.000.000 -93.68%
2011 31.935.000.000 22.98%
2012 17.796.000.000 -79.45%
2013 51.366.000.000 65.35%
2014 32.085.000.000 -60.09%
2015 47.391.000.000 32.3%
2016 44.344.000.000 -6.87%
2017 73.240.000.000 39.45%
2018 39.207.000.000 -86.8%
2019 33.995.000.000 -15.33%
2020 38.361.000.000 11.38%
2021 67.362.000.000 43.05%
2022 45.363.000.000 -48.5%
2023 67.556.000.000 32.85%
2023 23.411.000.000 -188.57%
2024 16.895.000.000 -38.57%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Terumo Corporation Operating Cashflow
Year Operating Cashflow Growth
2000 25.222.000.000
2001 28.566.000.000 11.71%
2002 36.825.000.000 22.43%
2003 41.496.000.000 11.26%
2004 43.725.000.000 5.1%
2005 43.380.000.000 -0.8%
2006 43.123.000.000 -0.6%
2007 69.683.000.000 38.12%
2008 31.615.000.000 -120.41%
2009 67.352.000.000 53.06%
2010 46.828.000.000 -43.83%
2011 56.200.000.000 16.68%
2012 50.270.000.000 -11.8%
2013 96.259.000.000 47.78%
2014 73.110.000.000 -31.66%
2015 80.303.000.000 8.96%
2016 80.862.000.000 0.69%
2017 114.562.000.000 29.42%
2018 93.571.000.000 -22.43%
2019 117.479.000.000 20.35%
2020 121.485.000.000 3.3%
2021 141.467.000.000 14.12%
2022 117.536.000.000 -20.36%
2023 146.330.000.000 19.68%
2023 42.148.000.000 -247.18%
2024 35.699.000.000 -18.06%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Terumo Corporation Capital Expenditure
Year Capital Expenditure Growth
2000 15.326.000.000
2001 13.602.000.000 -12.67%
2002 13.469.000.000 -0.99%
2003 1.055.000.000 -1176.68%
2004 2.777.000.000 62.01%
2005 2.196.000.000 -26.46%
2006 18.001.000.000 87.8%
2007 15.954.000.000 -12.83%
2008 20.241.000.000 21.18%
2009 19.716.000.000 -2.66%
2010 22.233.000.000 11.32%
2011 24.265.000.000 8.37%
2012 32.474.000.000 25.28%
2013 44.893.000.000 27.66%
2014 41.025.000.000 -9.43%
2015 32.912.000.000 -24.65%
2016 36.518.000.000 9.87%
2017 41.322.000.000 11.63%
2018 54.364.000.000 23.99%
2019 83.484.000.000 34.88%
2020 83.124.000.000 -0.43%
2021 74.105.000.000 -12.17%
2022 72.173.000.000 -2.68%
2023 78.774.000.000 8.38%
2023 18.737.000.000 -320.42%
2024 18.804.000.000 0.36%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Terumo Corporation Equity
Year Equity Growth
2000 172.326.000.000
2001 179.922.000.000 4.22%
2002 184.524.000.000 2.49%
2003 195.101.000.000 5.42%
2004 219.904.000.000 11.28%
2005 273.358.000.000 19.55%
2006 289.248.000.000 5.49%
2007 288.867.000.000 -0.13%
2008 278.166.000.000 -3.85%
2009 317.139.000.000 12.29%
2010 335.456.000.000 5.46%
2011 352.537.000.000 4.85%
2012 437.907.000.000 19.5%
2013 496.243.000.000 11.76%
2014 573.520.000.000 13.47%
2015 511.543.000.000 -12.12%
2016 489.552.000.000 -4.49%
2017 550.435.000.000 11.06%
2018 698.112.000.000 21.15%
2019 754.882.000.000 7.52%
2020 856.662.000.000 11.88%
2021 1.012.313.000.000 15.38%
2022 1.111.063.000.000 8.89%
2023 1.327.090.000.000 16.28%
2023 1.260.996.000.000 -5.24%
2024 1.418.461.000.000 11.1%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Terumo Corporation Assets
Year Assets Growth
2000 281.604.000.000
2001 284.667.000.000 1.08%
2002 288.122.000.000 1.2%
2003 293.839.000.000 1.95%
2004 312.455.000.000 5.96%
2005 354.597.000.000 11.88%
2006 367.079.000.000 3.4%
2007 410.918.000.000 10.67%
2008 379.064.000.000 -8.4%
2009 425.507.000.000 10.91%
2010 420.037.000.000 -1.3%
2011 692.520.000.000 39.35%
2012 771.030.000.000 10.18%
2013 832.812.000.000 7.42%
2014 992.070.000.000 16.05%
2015 901.684.000.000 -10.02%
2016 1.021.403.000.000 11.72%
2017 1.078.981.000.000 5.34%
2018 1.120.790.000.000 3.73%
2019 1.241.355.000.000 9.71%
2020 1.351.192.000.000 8.13%
2021 1.473.693.000.000 8.31%
2022 1.602.225.000.000 8.02%
2023 1.831.402.000.000 12.51%
2023 1.748.396.000.000 -4.75%
2024 1.868.956.000.000 6.45%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Terumo Corporation Liabilities
Year Liabilities Growth
2000 109.278.000.000
2001 104.745.000.000 -4.33%
2002 103.598.000.000 -1.11%
2003 98.738.000.000 -4.92%
2004 92.518.000.000 -6.72%
2005 81.239.000.000 -13.88%
2006 77.831.000.000 -4.38%
2007 121.964.000.000 36.19%
2008 100.898.000.000 -20.88%
2009 108.368.000.000 6.89%
2010 84.581.000.000 -28.12%
2011 339.983.000.000 75.12%
2012 333.123.000.000 -2.06%
2013 336.569.000.000 1.02%
2014 418.550.000.000 19.59%
2015 390.141.000.000 -7.28%
2016 531.851.000.000 26.64%
2017 528.546.000.000 -0.63%
2018 422.678.000.000 -25.05%
2019 486.473.000.000 13.11%
2020 494.530.000.000 1.63%
2021 461.380.000.000 -7.18%
2022 491.162.000.000 6.06%
2023 504.309.000.000 2.61%
2023 487.400.000.000 -3.47%
2024 450.492.000.000 -8.19%

Terumo Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
649.76
Net Income per Share
79.28
Price to Earning Ratio
37.07x
Price To Sales Ratio
4.52x
POCF Ratio
25.58
PFCF Ratio
47.36
Price to Book Ratio
3.08
EV to Sales
4.52
EV Over EBITDA
18.67
EV to Operating CashFlow
25.58
EV to FreeCashFlow
47.36
Earnings Yield
0.03
FreeCashFlow Yield
0.02
Market Cap
4.363,26 Bil.
Enterprise Value
4.363,13 Bil.
Graham Number
1305.37
Graham NetNet
23.2

Income Statement Metrics

Net Income per Share
79.28
Income Quality
1.25
ROE
0.09
Return On Assets
0.06
Return On Capital Employed
0.09
Net Income per EBT
0.75
EBT Per Ebit
1.03
Ebit per Revenue
0.16
Effective Tax Rate
0.25

Margins

Sales, General, & Administrative to Revenue
0.27
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.53
Operating Profit Margin
0.16
Pretax Profit Margin
0.16
Net Profit Margin
0.12

Dividends

Dividend Yield
0.01
Dividend Yield %
0.82
Payout Ratio
0.28
Dividend Per Share
24

Operating Metrics

Operating Cashflow per Share
114.89
Free CashFlow per Share
62.05
Capex to Operating CashFlow
0.46
Capex to Revenue
0.08
Capex to Depreciation
0.98
Return on Invested Capital
0.07
Return on Tangible Assets
0.09
Days Sales Outstanding
70.6
Days Payables Outstanding
69.19
Days of Inventory on Hand
239.24
Receivables Turnover
5.17
Payables Turnover
5.28
Inventory Turnover
1.53
Capex per Share
52.84

Balance Sheet

Cash per Share
131,26
Book Value per Share
955,29
Tangible Book Value per Share
539.72
Shareholders Equity per Share
955.29
Interest Debt per Share
133.14
Debt to Equity
0.14
Debt to Assets
0.1
Net Debt to EBITDA
-0
Current Ratio
2.98
Tangible Asset Value
801,40 Bil.
Net Current Asset Value
258,28 Bil.
Invested Capital
1518458000000
Working Capital
470,93 Bil.
Intangibles to Total Assets
0.33
Average Receivables
183,34 Bil.
Average Payables
90,28 Bil.
Average Inventory
293354000000
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Terumo Corporation Dividends
Year Dividends Growth
2000 17
2001 17 0%
2002 15 -13.33%
2003 25 40%
2004 34 26.47%
2005 44 22.73%
2006 28 -57.14%
2007 60 53.33%
2008 68 11.76%
2009 64 -6.25%
2010 64 0%
2011 38 -68.42%
2012 88 56.82%
2013 102 13.73%
2014 87 -17.24%
2015 70 -24.29%
2016 80 12.5%
2017 90 11.11%
2018 108 16.67%
2019 82 -31.71%
2020 56 -46.43%
2021 60 6.67%
2022 74 18.92%
2023 86 13.95%
2024 35 -145.71%
2025 0 0%

Terumo Corporation Profile

About Terumo Corporation

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

CEO
Mr. Hikaru Samejima
Employee
30.207
Address
2-44-1, Hatagaya
Tokyo, 151-0072

Terumo Corporation Executives & BODs

Terumo Corporation Executives & BODs
# Name Age
1 Ms. Miho Mizuguchi
Executive Officer, Chief Legal Officer and GM of CLO Office, Legal & Compliance Department
70
2 Tomoko Adachi
Chief Human Resources Officer & Group Executive Officer
70
3 Itaru Sakaguchi
Group Managing Executive Officer
70
4 Mr. Kazunori Hirose
Director & Group Managing Executive Officer
70
5 Fumihisa Hirose
Group Managing Executive Officer
70
6 Mr. Hikaru Samejima
Representative Director, President & Chief Executive Officer
70
7 Shinji Omori
Chief Technology Officer, GM of DX Promotion Dept. R&D Division and Executive Officer
70
8 Jin Hagimoto
Chief Financial Officer, Chief Information Officer, GM of CFO Office, Controller & Treasury Tax Dept., J-SOX Office, IT Planning
70
9 James Rushworth
Group Executive Officer & Chief Commercial Officer
70
10 Toshihiko Osada
Group Senior Managing Executive Officer & Director
70

Terumo Corporation Competitors